Lymphoma Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

National Cancer Survivors Day 2026: Why Survivorship Care Needs a Long-Term Strategy

World Blood Cancer Day 2026: New FDA Approvals and Phase III Readouts

Roche’s Subcutaneous Lunsumio Velo Receives FDA Approval for Follicular Lymphoma

January 21, 2026

World Blood Cancer Day 2025: New Strides in Treating Leukemia, Lymphoma and Rare Blood Malignancies

Life Science Podcast

Innovating Immune-Modulating Therapies in Autoimmune Disorders ft. Dr. Mario Marcondes, VP Head of Clinical Development, Nektar Therapeutics

February 5, 2025

Roche’s VENTANA Assay for B-Cell Lymphoma Gets FDA Clearance

January 13, 2025

Life Science Podcast

A Unique Approach to in vivo CAR T Therapy and New Advancements in the Field

October 9, 2024

World Lymphoma Awareness Day 2024: Building Support, Education, Treatment Advances

September 16, 2024

Roche’s Columvi Becomes Second Bispecific Approved for Diffuse Large B-Cell Lymphoma

Epkinly (Epcoritamab) Approved as First Bispecific Antibody for Most Common Non-Hodgkin’s Lymphoma

Interview About New Follicular Lymphoma Drug with Genentech’s Dr. Ginna Laport

February 24, 2023

Jaypirca (pirtobrutinib) Is Now FDA Approved to Treat Relapsed or Refractory Mantle Cell Lymphoma

February 3, 2023

Brukinsa (zanubrutinib) Gets FDA Approval for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

January 26, 2023

Lunsumio Gets FDA Accelerated Approval as Third Line Treatment for Follicular Lymphoma

January 9, 2023

Breyanzi (lisocabtagene maraleucel) Gets FDA Approval for Relapsed or Refractory LBCL After One Prior Therapy

Kymriah Approved for Additional Indication for Adults with Relapsed/Refractory Follicular Lymphoma

Next Page »